A B Smith

Health Hazards Evaluation Report No. HETA-81-055-954, Cotter Corporation, Canon City, Colorado

D. B. Baker, William E. Halperin, M Thun, 1981 .

Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

J Q Trojanowski, A B Smith, J. Trojanowski, 2011, Current topics in medicinal chemistry.

The design and synthesis of 2,5-linked pyrrolinones. A potential non-peptide peptidomimetic scaffold.

A B Smith, R. Hirschmann, P. Sprengeler, 1996, Bioorganic & medicinal chemistry.

Synthesis of polypyrrolinones on solid support.

A B Smith, R. Hirschmann, R Hirschmann, 2000, Organic letters.

Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis.

A B Smith, M. Cichy-Knight, W. Shakespeare, 1998, Journal of medicinal chemistry.

Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.

A B Smith, C. Strader, M. Cichy-Knight, 1996, Journal of medicinal chemistry.

An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.

A B Smith, P L Darke, W A Schleif, 1997, Journal of medicinal chemistry.